Publikasi Scopus FKUI 2021 per tanggal 31 Oktober 2021 (739 artikel)

William W., Ascobat P., Instiaty I., Agustin H.
57222750602;55795863600;55703138400;56135125000;
Outcomes of Daily Dose versus Part-daily Dose Treatment for Lung Tuberculosis: A Real-World Database Study in an Indonesian Hospital
2021
Acta medica Indonesiana
53
1
18
23
1. Department of Pharmacology and Therapeutics, Faculty of Medicine Universitas Indonesia, Indonesia. 2. Department of Pharmacology, Faculty of Medicine, University of Christian Krida WacanaJakarta, Indonesia
William, W., 1. Department of Pharmacology and Therapeutics, Faculty of Medicine Universitas Indonesia, Indonesia. 2. Department of Pharmacology, Faculty of Medicine, University of Christian Krida WacanaJakarta, Indonesia; Ascobat, P.; Instiaty, I.; Agustin, H.
BACKGROUND: a meta-analysis of randomized control trials (RCTs) on category I pulmonary tuberculosis (PTB) treatments showed that either part-daily (2RHZE/4R3H3) or daily dose (2RHZE/4RH) had the same failure and recurrence rates. However, the World Health Organization (WHO) concluded that the part-daily dose had higher failure and recurrence rates. Therefore, this study was conducted to compare the treatment outcomes between both regimens, whether daily dose regimen has a better treatment outcome than part-daily dose regimen, and the adverse effects between both regimens. METHODS: this was an analytic cross-sectional study of patients at the Persahabatan General Hospital, over the period of January 2015-June 2018. Data were taken from medical records and supported by telephone interviews, each regimen group had 175 patients. RESULTS: there were no significant differences for success rates (p=0.470), lost to follow up rates (p=0.659), failure rates (p=1.000), death rates (p=1.000), and adverse effects in the continuation phase (p=0.324) between the groups. There were, however, significant differences in cure rates (p < 0.001) and complete treatment rates (p<0.001) between the groups. CONCLUSION: the cure rate and complete treatment rate were found to be better for the part-daily than the daily doses. The success rate of both regimens were the same as Indonesia's target (90%). In the continuation phase, there were no significant difference of adverse effects between both regimens.
Adverse effects; dose regimen; pulmonary tuberculosis; treatment outcomes
NLM (Medline)
1259326
33818403
Article
Q3
321
14162